Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma

Table 2 Summary of tumor response and survival outcomes according to Response Evaluation Criteria in Solid Tumors 1.0 criteria

Outcomes	Observation group, n = 34	Control group, n = 30	P value
Best tumor response
Complete response	0 (0)	0 (0)
Partial response	11 (32.4)	6 (20.0)
Stable disease	19 (55.9)	18 (60.0)
Progressive disease	4 (11.8)	6 (20)
Objective response rate	11 (32.4)	6 (20)
Disease control rate	30 (88.2)	24 (80)
Median OS in month	22.1 ± 2.6 (16.3-27.6)	17.8 ± 2.3 (12.9-22.8)	< 0.05
Median PFS in month	12.2 ± 3.1 (5.5-18.3)	10.1 ± 2.2 (5.8-14.2)	< 0.05

¹Data are n (%) or mean ± standard deviation (95% confidence interval).

OS: Overall survival; PFS: Progression-free survival.